dc.contributor.author |
Castro, Betsy E. |
|
dc.contributor.author |
Berrio, Maritza |
|
dc.contributor.author |
Vargas, Monica L. |
|
dc.contributor.author |
Carvajal, Lina P. |
|
dc.contributor.author |
Millan, Lina V. |
|
dc.contributor.author |
Rios, Rafael |
|
dc.contributor.author |
Hernandez, Angie K. |
|
dc.contributor.author |
Rincon, Sandra |
|
dc.contributor.author |
Cubides, Paola |
|
dc.contributor.author |
Forero, Erika |
|
dc.contributor.author |
Dinh, An |
|
dc.contributor.author |
Seas Ramos, Carlos Rafael |
|
dc.contributor.author |
Munita, Jose M. |
|
dc.contributor.author |
Arias, Cesar A. |
|
dc.contributor.author |
Reyes, Jinnethe |
|
dc.contributor.author |
Diaz, Lorena |
|
dc.date.accessioned |
2020-07-14T00:01:03Z |
|
dc.date.available |
2020-07-14T00:01:03Z |
|
dc.date.issued |
2020 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/8258 |
|
dc.description.abstract |
BACKGROUND: Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures. OBJECTIVES: To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries. METHODS: We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006-08 and 2011-14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes. RESULTS: A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006–08 and 2011–14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87–0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins. CONCLUSIONS: The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Oxford University Press |
|
dc.relation.ispartofseries |
Journal of Antimicrobial Chemotherapy |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
phenotype |
en_US |
dc.subject |
vancomycin |
en_US |
dc.subject |
gait |
en_US |
dc.subject |
heterogeneity |
en_US |
dc.subject |
agar |
en_US |
dc.subject |
genome |
en_US |
dc.subject |
latin america |
en_US |
dc.subject |
methicillin-resistant staphylococcusaureus |
en_US |
dc.subject |
whole genome sequencing |
en_US |
dc.title |
Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1093/jac/dkaa221 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.03.08 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.05 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#1.06.01 |
|
dc.relation.issn |
1460-2091 |
|